Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 8/2020

23.05.2020 | Original Article – Cancer Research

IL-10 c.-592C>A (rs1800872) polymorphism is associated with cervical cancer

verfasst von: Ana Paula Lombardi Pereira, Kleber Paiva Trugilo, Nádia Calvo Martins Okuyama, Michelle Mota Sena, José D’Oliveira Couto-filho, Maria Angelica Ehara Watanabe, Karen Brajão de Oliveira

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Interleukin-10 (IL-10) is an immunoregulatory cytokine and its cervical and serum concentrations have been associated with a poor prognosis of cervical cancer. The rs1800872 polymorphism (c.-592C>A) in the promotor region of the IL-10 gene affects the production and expression of IL-10 and thus is able to determine the immune response profile in the cervix. Therefore, the aim of this work is to state the association between IL-10 c.-592C>A polymorphism and cervical cancer.

Methods

Genomic DNA was extracted from patient’s peripheral blood and tumor biopsy. Socio-demographic, sexual behavior and reproductive characteristics data were collected using a questionnaire.

Results

Co-dominant model in logistic binary regression adjusted for confounders, showed that patients presenting with C/A genotype had 2.15 times more chances for developing cervical cancer (OR 2.15; CI95% 1.02–4.56). The dominant model, C/A + A/A, was also independently associated with 2.71 times more chances for cervical cancer development when compared to control patients (OR 2.71; CI95% 1.05–4.47).

Conclusion

Our study analyses show the association between cervical cancer and IL-10 c.-592C>A polymorphism, demonstrating that the allele A presence was independently associated with higher risks of cervical cancer development.
Literatur
Zurück zum Zitat Appleby P, Beral V, Berrington De González A et al (2006) Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 118:1481–1495. https://doi.org/10.1002/ijc.21493 CrossRefPubMed Appleby P, Beral V, Berrington De González A et al (2006) Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 118:1481–1495. https://​doi.​org/​10.​1002/​ijc.​21493 CrossRefPubMed
Zurück zum Zitat Bhairavabhotla RK, Verm V, Tongaonkar H et al (2007) Role of IL-10 in immune suppression in cervical cancer. Indian J Biochem Biophys 44:350–356PubMed Bhairavabhotla RK, Verm V, Tongaonkar H et al (2007) Role of IL-10 in immune suppression in cervical cancer. Indian J Biochem Biophys 44:350–356PubMed
Zurück zum Zitat INCA - Instituto Nacional de Câncer José Alencar Gomes da Silva (2016) Diretrizes Brasileiras para o Rastreamento de Câncer de Colo de Útero. Ministério da Saúde, 2nd edn. Rio de Janeiro, RJ INCA - Instituto Nacional de Câncer José Alencar Gomes da Silva (2016) Diretrizes Brasileiras para o Rastreamento de Câncer de Colo de Útero. Ministério da Saúde, 2nd edn. Rio de Janeiro, RJ
Zurück zum Zitat Reeves G, Sweetland S, Kjaer S et al (2006) Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 119:1108–1124. https://doi.org/10.1002/ijc.21953 CrossRef Reeves G, Sweetland S, Kjaer S et al (2006) Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 119:1108–1124. https://​doi.​org/​10.​1002/​ijc.​21953 CrossRef
Zurück zum Zitat Sasagawa T, Takagi H, Makinoda S (2012) Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. J Infect Chemother 18:807–815CrossRef Sasagawa T, Takagi H, Makinoda S (2012) Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. J Infect Chemother 18:807–815CrossRef
Zurück zum Zitat WHO - World Health Organization (2016) UN Joint Global Programme on Cervical Cancer Prevention and Control WHO - World Health Organization (2016) UN Joint Global Programme on Cervical Cancer Prevention and Control
Metadaten
Titel
IL-10 c.-592C>A (rs1800872) polymorphism is associated with cervical cancer
verfasst von
Ana Paula Lombardi Pereira
Kleber Paiva Trugilo
Nádia Calvo Martins Okuyama
Michelle Mota Sena
José D’Oliveira Couto-filho
Maria Angelica Ehara Watanabe
Karen Brajão de Oliveira
Publikationsdatum
23.05.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 8/2020
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-020-03256-0

Weitere Artikel der Ausgabe 8/2020

Journal of Cancer Research and Clinical Oncology 8/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.